A recent retrospective study evaluated the efficacy and safety of novel biological therapies in treating very severe psoriasis, a condition that significantly impacts patients’ quality of life. The research analyzed data from 40 patients with very severe psoriasis who received biological agents for at least 16 weeks. The study tracked disease severity using the PASI score at weeks 16, 52, 104, and 156, along with monitoring treatment discontinuation rates and adverse events. Results showed substantial improvement in PASI scores over time, with a significant proportion of patients achieving PASI90 and PASI100 at various intervals. Moreover, the treatment was generally well tolerated, with only a small number of patients discontinuing due to complete remission, and mild adverse events reported by a minority. Overall, the findings suggest that biological therapies are both effective and safe for managing very severe psoriasis over the long term. The study underscores the importance of these treatments in addressing the substantial burden of the disease on patients’ lives and highlights the need for further research to optimize therapeutic strategies for severe cases.

Reference: Fiorillo G, Ibba L, Gargiulo L, Narcisi A, Costanzo A, Valenti M. Effectiveness and Safety of Biological Therapies in Very Severe Plaque Psoriasis: A Real-Life Retrospective Study. J Pers Med. 2024 Feb 7;14(2):186. doi: 10.3390/jpm14020186. PMID: 38392619; PMCID: PMC10890562.